ADH-1 trifluoroacetate is a selective and competitive N-cadherin antagonist with potential antitumor and anti-angiogenic activities; it inhibits collagen I-mediated changes and N-cadherin-induced cell motility in pancreatic cancer cells in vitro; induces apoptosis in a dose-dependent and N-cadherin-dependent manner; significantly prevents tumor growth and metastasis in a mouse model of pancreatic cancer; inhibits tumor cell invasion and metastasis in an orthotopic pancreatic cancer model using N-cadherin-overexpressing BxPC-3 cells; enhances the efficacy of regionally infused melphalan in melanoma tumor models; increases phosphorylation of AKT at serine 473 in A375 xenografts (but not in DM443 xenografts); and slightly reduces N-cadherin expression in both xenograft models.